Abstract

154P Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Oxaliplatin in ovarian cancer
A Du Bois ... W.W Ten Bokkel Huinink
Annals of Oncology | VOL. 10
A Du Bois, et. al.A Du Bois ... W.W Ten Bokkel Huinink
01 Jan 1998
Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
Perry D Nisen ... Gary J Kelloff
Clinical cancer research : an official journal of the American Association for Cancer Research | VOL. 10
Perry D Nisen, et. al.Perry D Nisen ... Gary J Kelloff
01 Jun 2004
Identification of PKP 2/3 as potential biomarkers of ovarian cancer based on bioinformatics and experiments
Lingling Gao ... Qian Guo
Cancer Cell International | VOL. 20
Lingling Gao, et. al.Lingling Gao ... Qian Guo
17 Oct 2020
SOX9/NFIA promotes human ovarian cancer metastasis through the Wnt/β-catenin signaling pathway
Xian Feng ... Di Zhang
Pathology - Research and Practice | VOL. 248
Xian Feng, et. al.Xian Feng ... Di Zhang
08 Jun 2023
View more papers

More From: Immuno-Oncology and Technology

Paper Title
Journal
Date
Author
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy – a retrospective and biomarker study
Fernanda Costa Svedman ... Suzanne Egyhazi Brage
Immuno-Oncology and Technology | VOL. -
Fernanda Costa Svedman, et. al.Fernanda Costa Svedman ... Suzanne Egyhazi Brage
01 May 2024
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial
Caroline Dive ... Kirellos S Abbas
Immuno-Oncology and Technology | VOL. 22
Caroline Dive, et. al.Caroline Dive ... Kirellos S Abbas
18 Mar 2024
Table of Contents
-
Immuno-Oncology and Technology | VOL. 21
--
01 Mar 2024
Editorial Board
-
Immuno-Oncology and Technology | VOL. 21
--
01 Mar 2024
View more papers